-
Mosquitoes - dreaded creatures. But funny the way nature often leads the way.
-
While the media spotlight has shone brightly on implantable cardioverter defibrillators (ICDs) of late, their external cousins - automated external defibrillators (AEDs) - have grown in numbers and in technological complexity. AEDs have saved thousands of lives, but their...
-
Resverlogix (RVX; Calgary, Alberta), developer of compounds for use with medical devices, has found a partner for its early-stage pharma technology, ReVas, for a large cardiovascular application. The company will work with Medtronic (Minneapolis), to create a drug-eluting (DES) stent, as the med-tech titan seeks to be the third to enter the DES derby.
-
It is beginning to sink in. Women die of heart disease as often as men. Ad attempts are being made to emphasize that it is a greater cause of fatality than the more publicized threat of breast cancer.
-
The American College of Cardiology Foundation (ACCF; Bethesda, Maryland), along with key specialty and subspecialty societies, last week released appropriateness criteria for two relatively new clinical cardiac ...
-
Axordia (Sheffield, UK) reported plans for the clinical application of one of its proprietary stem cell lines in a next-generation stent that will prevent restenosis without the increased risk of late-stage thrombosis that can occur with existing drug-eluting stent (DES) devices.
-
ATS Medical (Minneapolis) reported that the U.S. Securities and Exchange Commission has declared effective the company's registration statement concerning its proposed acquisition of 3F Therapeutics (Lake Forest, California). Unveiled in January, the deal, with milestones, has been valued at $58 million. The company will hold its annual meeting on Sept. 25 for a vote on the acquisition.
-
St. Jude Medical (St. Paul, Minnesota) reported that it is combining its Cardiac Surgery and Cardiology divisions to create a new Cardiovascular division, effective Jan. 1, 2007.
-
Thomas Etergino has resigned as vice president and CFO of AtriCure (West Chester, Ohio). Until a successor is named, David Drachman, president/CEO, will manage company finances. AtriCure develops surgical devices that create precise lesions in soft and cardiac tissues.
-
